• Patient willing and able to sign informed consent and to follow the protocol requirements

• Female patients aged ≥ 18 years at the time of Screening

• Patient with Eastern Cooperative Oncology Group (ECOG) Performance Status \< 2

• Patients with breast cancer that meets the following criteria:

∙ A known case of histologically confirmed invasive breast carcinoma with a primary tumor size of \> 2 cm by standard local assessment technique

‣ stage at presentation: early stage (T2-3, N0-1, M0) or locally advanced (T2-3, N2 or N3, M0; T4a-c, any N, M0) or inflammatory (T4d, any N, M0)

• Patients with HER2 overexpression by Immunohistochemistry (IHC) (defined as IHC 3+, or IHC 2+ with Fluorescence In Situ Hybridization (FISH) confirmation) as per the American Society of Clinical Oncology/College of American Pathologist (ASCO-CAP) guidelines prior to Screening and confirmed centrally before randomization

• Patients with known HR-ve status (ER-negative and PR-negative) as per local laboratory prior to Screening and confirmed centrally before randomization

• Patient willing to undergo mastectomy or breast-conserving surgery after neoadjuvant therapy

• Patient who completes all necessary baseline laboratory and radiologic investigations prior to randomization as per Schedule of assessment (SoA)

• Patient with baseline left ventricular ejection fraction (LVEF) ≥ 55% measured by echocardiography (ECHO; preferred) or multiple-gated acquisition (MUGA) scan

⁃ Patient is eligible to participant if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: